胃肠道癌症药物市场（2026—2031）
胃肠道癌症药物市场规模预计由2026年的241.8亿美元增至2031年的301.3亿美元，预测期复合年增长率为4.50%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
胃肠道癌症药物市场规模预计由2026年的241.8亿美元增至2031年的301.3亿美元，预测期复合年增长率为4.50%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 4.5% | 机构预测 |
| 市场规模 | 2026 | USD 24.18 billion | 机构预测 |
| 市场规模 | 2031 | USD 30.13 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| application | oncology departments | 2025 | 68.760% |
| cancer_type | colorectal cancer | 2025 | 34.220% |
| end_user | hospitals | 2025 | 53.560% |
| geography | North America | 2025 | 39.440% |
| therapy | immunotherapy | 2025 | 58.600% |
关键结论
- application 维度中，oncology departments 在 2025 年的公开份额为 68.76%。
- cancer_type 维度中，colorectal cancer 在 2025 年的公开份额为 34.22%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 53.56%。
- geography 维度中，North America 在 2025 年的公开份额为 39.44%。
- therapy 维度中，immunotherapy 在 2025 年的公开份额为 58.6%。
主要参与者
- Novartis AG
- Merck & Co., Inc.
- AstraZeneca PLC
- Pfizer Inc.
- Eli Lilly and Company
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Precision oncology and biomarker-based treatment | +1.400% | Global, strongest in North America and Western Europe | Medium term (2-4 years) |
| First line immunotherapy combination use | +1.200% | Global, with the highest revenue impact in North America and East Asia | Short term (≤ 2 years) |
| Rising gastrointestinal cancer burden and earlier diagnosis | +0.900% | Global, with the greatest volume growth in Asia-Pacific, the Middle East and Africa, and South America | Long term (≥ 4 years) |
| Wider companion diagnostic use | +0.500% | North America and Europe, with expanding use in the Asia-Pacific | Medium term (2-4 years) |
| Perioperative and adjuvant drug treatment | +0.700% | Global, with early adoption in Europe and North America | Medium term (2-4 years) |
| Regional oncology biologics manufacturing | +0.300% | Asia-Pacific, with spillover into Middle East and Africa | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Cost and reimbursement barriers for biomarker-selected regimens | -1.000% | Global, with the highest impact in middle-income markets and European price-controlled systems | Medium term (2-4 years) |
| Biosimilar, generic, and mandatory price reduction pressure | -0.800% | Europe, Japan, and China, with a growing impact in South America | Short term (≤ 2 years) |
| Limited testing, infusion, and cell therapy capacity | -0.400% | Middle East and Africa, South America, and lower-income Asia-Pacific markets | Long term (≥ 4 years) |
| Manufacturing, cold chain, and injectable supply vulnerability | -0.300% | Global, with the highest exposure for single-source biologics | Short term (≤ 2 years) |
报告关注的关键问题
What is the size of the gastrointestinal cancer drugs market in 2026?
The gastrointestinal cancer drugs market size is USD 24.18 billion in 2026 and is projected to reach USD 30.13 billion by 2031 at a 4.50% CAGR.
Which gastrointestinal cancer type is growing fastest?
Pancreatic cancer is the fastest-growing category within the gastrointestinal cancer drugs market, with a 5.36% CAGR through 2031.
Which therapy type has the largest share in gastrointestinal cancer treatment?
Immunotherapy held 58.60% of revenue in the gastrointestinal cancer drugs market in 2025, while targeted therapy is projected to grow at a 6.56% CAGR.
Why are biomarker tests important for gastrointestinal cancer treatment?
In the gastrointestinal cancer drugs market, biomarker tests identify patients who may benefit from medicines targeting KRAS G12C, BRAF V600E, HER2, CLDN18.2, MSI-H/dMMR, and NRG1 fusions.
Which region is growing fastest for gastrointestinal cancer drugs?
Asia-Pacific is the fastest-growing region in the gastrointestinal cancer drugs market, at a projected 6.98% CAGR through 2031.
What limits access to advanced gastrointestinal cancer medicines?
The gastrointestinal cancer drugs market faces access limits from high treatment costs, diagnostic reimbursement gaps, biosimilar competition, and limited care infrastructure.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence